Adageis Allows Healthcare Providers Maximum Value-Based Care Revenue with Simplicity and Visibility

• The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue.
• The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care.
• Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue.

As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a growing healthcare technology company with a patented AI-driven platform, is offering providers tools that both simplify operations and improve financial performance under value-based care models.

The platform, rebranded as a fintech AI solution, focuses on helping providers understand how their clinical decisions tie directly to revenue. According to Adageis, three central benefits stand out:

• Ease of use
• Visibility into insurance contracts
• Long-term financial tracking

One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards.

Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.

The software supports this by providing direct insight into performance metrics tied to value-based care models, allowing practices to focus on both patient outcomes and financial sustainability.

For many clinics, understanding how much they should be paid under different insurance agreements remains a challenge. Adageis aims to address that, by enabling its software to help providers determine how well they are being compensated for the care they deliver.

This is particularly important for high-performing clinics that may be underpaid for exceeding quality benchmarks. With Adageis, practices can identify which contracts are more favorable and structure their care delivery accordingly.

This functionality also assists newer practices that are transitioning away from fee-for-service models. The platform helps them assess which payer contracts are most lucrative under value-based frameworks, supporting growth without sacrificing quality.

In addition to point-in-time analysis, Adageis helps providers track how their focus on quality care is rewarded financially. By visualizing financial trends alongside patient care metrics, providers can make strategic decisions with better confidence. Clinics can see not just how they’re performing today, but how that performance evolves as care models change.

Beyond software, Adageis positions itself as an advocate for its clients. The company works directly with insurance payers on behalf of providers, helping them navigate negotiations and understand their entitlements. This hands-on approach is especially beneficial for small practices with limited administrative support.

The company also continues to work with investors to expand its offerings, aiming to develop tools tailored to the needs of small and mid-sized clinics.

Adageis’s patented ProActive Care Platform offers full integration with widely used Electronic Health Record (“EHR”) systems including AthenaHealth, Cerner, Epic, and others. This ensures that providers don’t need to overhaul their IT infrastructure to benefit from the system.

Additionally, its Risk Engine (“PRE”) identifies high-risk patients and care gaps, helping clinics deliver timely interventions and reduce avoidable costs. The platform supports proactive care, monitoring patient health beyond traditional office visits.

As of April 2025, Adageis covered over 260,000 patient lives. By the end of Q2, it expects to double that figure to 580,000 and reach $100,000 in monthly recurring revenue. The company also anticipates onboarding two to three new clients each month.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN